The first independent ratings of GLP-1 telehealth platforms arrived this week, with a design choice buried in the methodology that matters more to consumers than any individual score: every company selling only compounded weight-loss drugs was excluded from the analysis entirely.
U.S. News & World Report published its debut ratings for the 2026-2027 Best GLP-1 Telehealth Platforms on August 12, 2026. The evaluation covered 20 online platforms offering FDA-approved brand-name medications, including Wegovy, Zepbound, Ozempic, and Foundayo, drawing on 14,161 data points and a survey of 1,251 U.S. adults who had used a GLP-1 telehealth platform in the past year. Eleven platforms ultimately met the publication's standards.
The exclusion line is the news. According to the ratings methodology, companies that offer only compounded GLP-1 medications were not included. Where a rated platform sells both branded and compounded products, the ratings evaluated only aspects related to FDA-approved brand-name medications.
The Boundary Is a Safety Judgment, Not a Filing Category
Compounded semaglutide and tirzepatide are not FDA-approved products, and the ratings treated that as disqualifying rather than as a footnote.
Gretel Schueller, managing editor of health at U.S. News, said companies selling only compounded medications were excluded because those versions are not reviewed by the FDA for safety or quality, which can introduce contamination or dosing errors.
That reasoning tracks documented problems rather than theoretical ones. Approved GLP-1 products come in prefilled, calibrated pens. Many compounded versions arrive in multidose vials, from which a patient draws a dose with a syringe, and the FDA has documented cases in which people administered many times the intended amount due to measurement error. Concentrations differ between compounded products, so units are not interchangeable between suppliers. MedicalDaily has reported that poison control calls involving these medications rose sharply as use expanded.
Composition is a second issue. Some compounded products use unapproved salt forms of the active drug or add ingredients that were never tested alongside these medications in human trials, which MedicalDaily examined earlier this year.
The Price Comparison the Exclusion Reshapes
For a consumer comparing options online, the practical effect of the exclusion is that the cheapest listings are not included.
Compounded versions have been advertised at a fraction of brand-name prices, sometimes for $100 or $200 a month, compared with four-figure list prices for approved products. A shopper who opens the ratings expecting a price-sorted marketplace will find that the least expensive tier is simply absent, and the reason is not oversight.
The legal ground has also shifted underneath that market. Tirzepatide was removed from the FDA shortage list in December 2024, and semaglutide in February 2025, which removed the legal basis for compounding copies of the approved drugs. The FDA has since proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that large outsourcing facilities may use, a proposal MedicalDaily covered when the comment period closed.
None of that makes an approved product affordable for a household without coverage, and the ratings do not solve that problem. What the exclusion does is separate the affordability question from the safety question, so a consumer is not comparing a reviewed product and an unreviewed one as though they were the same purchase at different prices.
The Six Criteria Worth Borrowing
The rating pillars are useful to consumers even outside the ranked list, because they describe what adequate care through a screen actually looks like.
Platforms were scored on a five-point scale across clinical support (weighted at 25 percent), screening rigor (20 percent), transparency (17 percent), insurance assistance (15 percent), supplemental care (13 percent), and overall customer satisfaction (10 percent).
Screening rigor and clinical support carry the most weight combined, reflecting what these drugs require. Schueller said patients should confirm that any platform they use orders baseline blood work, including tests of liver and kidney function, before issuing a prescription. A service that prescribes based on a questionnaire alone, with no laboratory work and no scheduled follow-up, is not providing the monitoring these medications require.
Insurance assistance at 15 percent is the pillar most connected to whether treatment continues. Coverage for weight management remains inconsistent, and a platform that helps with prior authorization affects whether a patient can stay on a drug rather than starting and stopping.
Reasonable questions to ask any platform include whether the medication is FDA-approved, what baseline labs are required, who the prescribing clinician is and whether they are licensed in the patient's state, what follow-up is scheduled, and what happens if side effects appear between visits.
The Limits of a Debut Rating
Several caveats belong high rather than buried, because this is a first edition.
These ratings are the product of a media organization applying its own criteria, not a regulatory assessment or a clinical guideline. The weightings are editorial judgments, and a different set of weights would produce a different ranking. U.S. News says companies do not pay to be included or rated, but also discloses that it may earn a commission when readers buy through its links, which is a commercial relationship worth knowing about. Customer satisfaction data came from 1,251 users, a meaningful but self-selected sample.
The ratings also do not evaluate compounded products, which means they say nothing about the relative quality of platforms in that segment. Absence from the list is not a finding against a specific company so much as a decision not to assess that category.
About 11 percent of Americans now take a GLP-1 for weight loss, according to Gallup, so the audience making these decisions is large and growing. U.S. News describes these as debut ratings, which suggests annual updates. Readers should also watch for the FDA's final decision on the bulk substances proposal, which, if adopted as written, would further narrow the compounded market. The publisher's own announcement of the ratings advises consulting a medical provider before starting treatment.
Anyone considering treatment should treat any online rating as a starting point for a conversation with a clinician rather than a substitute for one. The most durable takeaway from this release is the boundary itself: a product that no regulator has reviewed is a different kind of purchase from one that has been, regardless of the price difference.
Key Questions Answered
What was published? U.S. News & World Report released its debut ratings for the 2026-2027 Best GLP-1 Telehealth Platforms on August 12, 2026, evaluating 20 platforms and identifying 11 that met its standards.
Why were some companies excluded? Companies selling only compounded GLP-1 medications were left out because those products are not reviewed by the FDA for safety or quality.
Does exclusion mean a company is unsafe? Not necessarily. It means the ratings did not assess that category, so absence is not a company-specific finding.
What were platforms scored on? Clinical support at 25 percent, screening rigor at 20 percent, transparency at 17 percent, insurance assistance at 15 percent, supplemental care at 13 percent, and customer satisfaction at 10 percent.
Why are compounded versions riskier? They are not FDA-reviewed, often come in multidose vials that require the patient to measure a dose, and have concentrations that vary between suppliers, which has led to documented dosing errors.
What should I ask a telehealth platform? Whether the drug is FDA-approved, what baseline blood work is required, who prescribes it and where they are licensed, what follow-up is scheduled, and how side effects are handled.
Is this a medical recommendation? No. These are media ratings based on editorial criteria. Treatment decisions should involve a qualified clinician.
